Doximity 2027 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q2 FY27 revenue was $174.5 million, up 4% year over year and above guidance; CEO Jeff Tangney also described revenue as $175 million.
- Adjusted EBITDA was $89 million, representing a 51% margin, and exceeded the high end of guidance; non-GAAP gross margin was 88%, compared with 92% last quarter.
- Quarterly active workflow prescribers, including AI users, grew 34% year over year to a record high, with approximately half of the 1.8 million U.S. prescribers using Doximity in the quarter.
- Doximity’s health system AI client footprint grew to over 190 from 165 last quarter, including 10 of the nation’s top 20 hospitals; New York Presbyterian and UCSD Health were highlighted as clients.
- Top 20 hospital and pharma customers had 106% net revenue retention (NRR), while overall NRR was 103%; customers with more than $500,000 in annual spend represented 82% of revenue and grew 3% year over year to 124.
- Doximity ended Q2 FY27 with $713 million in cash, cash equivalents, and marketable securities, no debt, and $347 million remaining in its share repurchase program; it generated $91 million of free cash flow and repurchased $54 million of shares.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
I'll now hand the conference over to Perry Gold. Perry, please go ahead. Thank you, operator.
Hello and welcome to Doximity's fiscal 2027 second quarter earnings call. With me on the call today are Jeff Tangney, co-founder and CEO of Doximity, and Matt Sonefeldt, CFO. A complete disclosure of our results can be found in our press release issued earlier today, as well as in our related Form 8-K, along with a copy of our prepared remarks, all available on our website at investors.doximity.com. As a reminder, today's call is being recorded, and a replay will be available on our website. As part of our comments today, we will be making forward-looking statements. These statements are based on management's current views, expectations, and assumptions, and are subject to various risks and uncertainties. Actual results may differ materially, and we may disclaim any obligation to update any forward-looking statements or outlook.
Please refer to the risk factors in our annual report on Form 10-K, any subsequent Form 10-Qs, and any other reports and filings with the SEC that may be filed from time to time, including our upcoming filing on Form 10-Q. Our forward-looking statements are based on assumptions that we believe to be reasonable as of today's date, November 5, 2026. Of note, it is Doximity's policy to neither reiterate nor adjust the financial guidance provided on today's call unless it is also done through a public disclosure, such as a press release or through the filing of a Form 8-K. Today, we will discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results. A historical reconciliation to comparable GAAP metrics can be found in today's earnings release.
Finally, during the call, we may offer incremental metrics to provide greater insights into the dynamics of our business. These details may be one-time in nature, and we may or may not provide updates on those metrics in the future. I would now like to turn the call over to our CEO and co-founder, Jeff Tangney.
Jeff? Thanks, Perry, and thanks, everyone, for joining our second quarter earnings call.
Today, I will cover three things: our financials, AI accuracy, and engagement. First, our financials. Revenue was $175 million in Q2, up 4% year-on-year and 2% above the high end of our guidance. Even with over 6x growth year-on-year in our AI spend, our Q2 adjusted EBITDA margin was 51%, or $89 million, and 9% above the high end of our guidance. While this remains our AI investment year, we continue to have strong margins. Now to AI accuracy. It is by far the number one concern doctors have about AI. AI deals in probabilities. Patient care demands precision. All of us have had the experience of hitting refresh on an AI answer and getting a different response. Thankfully, accuracy is where we continue to lead the way.
For starters, we launched DoseCheck, a deterministic verifier for medication safety. In a study of over a quarter million AI drug dose queries across all major models, we found a 2.3% error rate. What is more, 40% of these errors are serious or even lethal. From a million AI drug queries, 9,000 patients could get hurt. That is too many. Our DoseCheck catches these errors using our built-in drug dataset. It is painstaking work, and we are proud to do it. Second, we are excited to add UpToDate to our AI answers. Every clinical AI model has read the National Library of Medicine, which has all of the journals and guidelines, but Wolters Kluwer's UpToDate stands alone as the proprietary gold standard reference for point of care. Their 7,600 physician authors provide unique advice about what to do when there is not an RCT, or randomized controlled trial, to answer the question.
We think this real-world medical layer is really important, and now it is one tap away inside of Doximity. Independent tests keep confirming our lead in accuracy and safety. In September, we joined other vertical AI leaders like Harvey in law and Sierra in customer service to create industry-specific benchmarks. When AI provider Fireworks graded the results, Doximity ranked first among 16 leading models, echoing our Stanford NOHARM study results in July. Physician input is critical to getting AI and medicine right. This quarter, we convened our Medical AI Summit, 150 physicians, chiefs, and chairs from our nation's best hospitals, joined by two former U.S. Surgeons General, Dr. Vivek Murthy and Dr. Regina Benjamin, to work through how we build clinical AI responsibly together. As a physicians-first company, this unique semi-annual event is our North Star and guides our roadmap. Finally, our engagement and client growth.
Quarterly active workflow prescribers, which includes our AI users, grew 34% year-on-year to record highs, accelerating from last quarter. For the first time, approximately half of all of the 1.8 million U.S. prescribers used us last quarter as part of their workflow. Our health system client footprint continued to grow as well, up over 190 on our AI suite from 165 last quarter, including 10 of the nation's top 20 hospitals. NewYork-Presbyterian now provides access to Doximity AI directly from its EHR, giving NewYork-Presbyterian, Columbia, and Weill Cornell Medicine clinicians convenient access to AI-powered tools and the latest medical research within their existing workflows. Over the past five years working with NewYork-Presbyterian, we have seen firsthand why they are consistently ranked among the nation's best hospitals, and we are excited to grow our AI toolset with them.
UCSD Health, the number 1 ranked hospital in San Diego, is another AI client and one of the first hospitals to adopt our new Patient Context feature. Directly from a patient's chart, our AI can read that patient's notes, labs, imaging, conditions, and coverage to give patient-specific answers and guideline-based treatment plans. It's the difference between a doctor asking a general medical question and asking about the patient in front of them. Our Patient Context feature is now available for thousands of doctors, and they're writing prompts half as long, 12 words versus our 24-word average, because they no longer have to retype the chart details into a search bar. Our AI already has the labs, notes, and problem list, so it can find the pertinent clinical details deep in their record. To fit more workflows, we're opening API access to our clinical intelligence layer.
If you're building time-saving tools for clinicians, we'd love to work with you. Just email us at bd@doximity.com. Last, on the pharma side, our AI Search commercial offering has been well received. 16 of the top 20 pharma companies have already purchased, with three more in contracting. More than 100 clients attended our pharma AI showcase last month, our biggest turnout ever. To sum up, with DoseCheck and UpToDate, we lead on AI accuracy and trust. With 190 health system AI clients and Patient Context, we lead on distribution and integration. With AI Search now available to our pharma clients, we're growing into a much larger market. As always, I'd like to end by thanking my Doximity teammates who continue to work incredibly hard to care for those who care for us.
With that, I'll hand it over to our CFO, Matt Sonefeldt, to walk us through our financials and guidance.
Matt? Thanks, Jeff. Q2 was another strong quarter for Doximity, with AI usage driving accelerated adoption of our broader workflow suite.
This validates our decision to expand AI investment in FY 2027. We also improved AI cost efficiency during the quarter, which helped drive higher-than-expected profitability. Turning to our top line, Q2 revenue of $174.5 million outperformed our guidance with 4% year-over-year growth. This growth comes against a difficult year-over-year comparison versus Q2 2026, when we benefited from rapid adoption of our multi-model integrated offering. Revenue upside in Q2 was driven by solid performance across our product portfolio, as well as growing interest in our AI Search product. Positive AI Search demand signals include pharma company customers purchasing on average more than two programs each, and the doubling of available conditions driven by customer interest.
We believe customer engagement with AI Search continues to drive broader momentum across our entire pharma portfolio. In terms of customer metrics, our top 20 hospital and pharma customers produced net revenue retention, or NRR, of 106%, with overall NRR at 103%. Customers with greater than $500,000 in annual spend represented 82% of revenue and grew 3% year-over-year to 124. As a reminder, these are trailing 12-month metrics. Turning to profitability, adjusted EBITDA in Q2 2027 was $89 million and represented a 51% margin. Outperformance was split evenly between the flow-through of higher-than-expected revenue and better-than-anticipated AI efficiency. Non-GAAP gross margin was 88% versus 92% last quarter. As we shared last quarter, the majority of the increase in cost of revenue reflects scaling our AI investment to support rapidly growing engagement. As a reminder, over 90% of our incremental AI cost is for clinician usage.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
16 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
